Methods: Patient sample included individuals with histolopathologicaly proven gastric cancer (n = 128, median of age 67.5, males/females 84/44); control group was represented by consecutive dyspeptic patients coming or upper gastrointestinal endoscopy (n = 146, median of age 61, males/females 55/91) having no evidence of gastric mucosa atrophy, without HP eradication and proton pump inhibitor use during the previous month. Presence of CagA, VacA, GroEL, gGT, HcpC, and UreA antibodies was detected by line immunoassay based test on recombinantly expressed HP proteins (recomLine, Microgen, Germany). Statistical tests: chi2test, logistic regression.
Results: Antibodies against CagA, VacA, GroEL were significantly more often found among cancer patients compared to the control group (89% vs 65.1%; 21.9% vs 12.3%; 83.6% vs 63%, respectively). Seropositivity against different proteins in relation to risk for gastric cancer is shown in the Table 1.
Table 1 Seropositivity against different HP proteins in relation to risk for gastric
Odds ratio 95% Confidence interval p-value
CagA 4.371 2.280–8.382 0.001
VacA 1.991 1.042–3.804 0.035
GroEL 2.991 1.681–5.320 0.001
UreA 0.958 0.513–1.790 0.893
HcpC 1.546 0.914–2.614 0.103
gGT 1.204 0.740–1.958 0.454
CagA/VacA/GroEL 5.073 1.8653–13.79 0.001
Conclusions: Seropositivity against CagA, VacA and GroEL was associated with increased risk for non-cardia gastric cancer while individuals with triple positivity showed even fivefold increased risk of gastric cancer.
|Number of pages||1|
|Publication status||Published - Sep 2014|
|Event||XXVIIth International Workshop on Helicobacter and Microbiota in Chronic Digestive Inflammation and Gastric Cancer - Rome, Italy|
Duration: 11 Sep 2014 → 13 Sep 2014
Field of Science
- 3.1 Basic medicine
- 3.2 Clinical medicine
- 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database